INTRODUCTION
Despite marked progress in reducing deaths from malaria, the disease remains a major cause of infant mortality in the developing world, with more than 500,000 estimated to die each year 1, 2 . In the absence of a fully protective vaccine 3 , chemotherapeutics constitute the best available clinical tool to prevent or treat malaria disease. The most effective formulations, and standard of care recommended by the World Health Organization (WHO), are based on combination therapies with endoperoxides such as artesunate, artemisinin and artemether, referred to as artemisinin-based combination therapies (ACTs). However, like every clinical antimalarial to date, evidence is growing for the emergence of resistance to ACTs, specifically in South East Asia though not as yet in Africa 4, 5 . To combat ACT resistance and prevent its potentially devastating spread to sub Saharan Africa new drugs are required with novel modes of action 6 .
In recent years, cell-based screens have demonstrated great power in their capacity to discover compounds for development as next generation antimalarials. Notably, several of these screens have repeatedly found compounds with activity against malaria parasite protein synthesis [7] [8] [9] .
Protein synthesis in the malaria parasite is an attractive target given its essential nature to parasite cell growth and development and the strong precedence for mRNA to protein translation as an antimicrobial target for bacterial infections 10 . Screening platforms to specifically identify compounds with similar activity against malaria would be a welcome addition to the antimalarial field to increase and differentiate the drug discovery pipeline. Towards this, two studies have devised formulation of a cell free in vitro translation (IVT) lysate 11 and its development towards a luciferase reporter assay 12 . This provides a foundation from which inhibitors specific to protein synthesis in the most virulent human malaria parasite, Plasmodium falciparum. Whilst some compounds have been screened with this in mind, for example assaying of the Medicines for Malaria Venture Malaria Box 12 (400 bioactive compounds with minimal human cytotoxicity profiles), the potential to translate such a platform to blind, high throughput (HTP) screening for compounds targeting the breadth of the protein translation machinery has not been fully realized.
To address this, we sought to develop an optimized 384-well-plate assay for HTP screening, applicable to a conventional laboratory spectrofluorometer and validated for its robustness, replicability and capacity to find inhibitors of protein synthesis with diverse modes of action as demonstrated with known translation inhibitors.
RESULTS AND DISCUSSION
Building on recent efforts to devise a protein translation assay applicable to HTP screening, we first optimized a protocol for large scale, yet reduced budget, protein lysate production, compatible with protein translation. For the production of 3-8 ml lysate, up to 6 liters of a high parasitemia P.
falciparum 3D7 culture were saponin-treated, with cytosolic extract released via nitrogen cavitation (see MATERIALS AND METHODS for details) ( Figure 1A ). This yielded on average a lysate with 1000-2000 µg/mL of total RNA as a measure for presence of ribosomal RNA and hence potential lysate activity. We next sought to develop a reporter system compatible with both a time course and endpoint plate-based assay with optimal signal to noise ratio but using reduced amounts of lysate. A parent vector, pHLH-1 13 , was used as the foundation for downstream expression plasmids, in which expression of Photinus pyralis firefly luciferase (luc) occurs under the control of flanking P. falciparum regulatory elements from the histidine rich proteins, namely the 5' promoter element from hrp3 and 3′ untranslated region (UTR) from hrp2. To generate mRNA from this vector in vitro, a T7-terminator was introduced after this expression cassette using site-directed mutagenesis, generating the vector pHLH-T7term (referred to as pHLH here for simplicity).
The mRNA from cDNA was generated by a high yield in vitro transcription protocol previously Having validated in vitro translation (IVT) with the luciferase reporter system, we next attempted to optimize our platform for high throughput (HTP). Initial assays were scaled down from 50 to 20 µl and performed in 384-well plates. Measurements from five endpoints (at 0-4h post assembly of lysate with energy, amino acids and mRNA), each set up in triplicate, following the incubation at 37˚C with shaking every 30 min in a plate reader were taken. For each time-point the luciferase reaction buffer was added directly into the test wells 10 minutes prior to measurement. An increase of detected luminescence demonstrated successful production of luciferase for at least 4h ( Figure   1D ).
We next aimed to investigate whether the continuous monitoring of the IVT might provide further information about the dynamics of parasite translation and drug dynamics over time. To this end, we explored generation of an mRNA reporter construct using conventional P. pyralis firefly luciferase versus an alternative green bioluminescence reporter from the click beetle Pyrophorus plagiophthalamus CBG99 15 . This was cloned into the pHLH construct replacing the luc expression cassette, generating a pH-CBG99-H expression vector with conserved flanking regulatory elements.
Customization of the luciferase reaction buffer (see MATERIALS AND METHODS), resulted in a 5-fold increase of the signal to noise, which permitted a direct test between firefly and click beetle luciferase 5'hrp3 and 3'hrp2 flanked constructs to ascertain the optimal construct for signal intensity and continuous production of oxyluciferin, detectable with a plate reader. Of note, luminescence deriving from CBG99 mRNA, but not Luc, produced a signal detectable with a peak at about 2.5 h post-set up using our customized luciferase reaction buffer, added at the start of the reaction/incubation time ( Figure 2A ). This suggested that the click beetle luciferase is either more stably produced over time or its activity more stable than that of firefly luciferase under our IVT assay conditions 15 ( Figure 2A ). We also explored the UTR-dependence of IVT using an alternative Comparison of the Pfhrp3 5' UTR with that from Pfeba-175, showed that whilst the eba-175 5'UTR is efficient in enabling IVT, as reported 12 , especially when compared to an EMCV IRES using parasite lysate, the hrp3 5'UTR is considerably more efficient and reliable (smaller variation of signal between single assays) under our IVT conditions ( Figure 2B ). Minimal translation was seen using the pIRES-CBG99 vector. pH-CBG99-H mRNA was therefore selected for all further screening using our customized reaction buffer, with peak luminescence seen around 120 minutes.
To validate the ability of the plate-based luminescence assay for drug screening, we tested its sensitivity to known translation inhibitors including CHX and emetine (EME) (both of which target the parasite ribosome 16 ) and halofuginone (HF) a direct target of the cytoplasmic Plasmodium protein translation enzyme prolyl-tRNA synthetase 17 . Assayed in triplicate in the same experiment, each of these drugs showed inhibition of in vitro translation at nanomolar concentrations when measured at 2 hours ( Figure 3A -C). Observed differences in the dynamics of the luminescence measured kinetically (time of onset, slope of increase, maximum and time-point at maximum measured luminescence) when assayed at 12 nM ( Figure 3D ) showed that each drug exhibited different residual activity. Whilst we have not explored this here, this may indicate that the assay could potentially determine not only translation inhibition during a screen (as an endpoint) but could be developed to interrogate potential mechanisms of action (as derived from the kinetics of activity) and stability of the drug when the whole profile of the curve of luciferase signal is considered. Work is ongoing towards validation of the concept. The dose dependency curves for the three drugs CHX, EME and HF ( Figure 3A -C) were broadly consistent with experimentally determined cell culture IC50 values for emetine dihydrochloride hydrate (±47 nM) 18 and HF (±9 nM) 17 though less accurate for CHX, which is extremely potent in cellular assays (0.6 nM 19 ). This verified the sensitivity of the IVT assay towards a least two classes of translation inhibitors, demonstrating its utility in detecting compounds beyond those targeting only the ribosome.
The Medicines for Malaria Venture (MMV) Malaria Box is a collection of 400 compounds representing families of structures identified as having activity against P. falciparum 20 . Some of these were recently shown to affect parasite in vitro translation 12 . Leading on from this we sought to validate the previously reported activity of candidate compounds compared to a third class of translation inhibitor, DDD107498, a current antimalarial in preclinical development that targets parasite protein translation via the translation elongation factor 2 (eEF2) 8 . Contrary to published findings 12 , measurement at 120 minutes did not show any substantial translation inhibition activity from the top 8 MMV compounds previously identified ( Figure 4A , highlighted (blue labels) besides 8 further random MMV compounds (black)). Where activity was seen it was inconsistent between replicate runs (e.g. compound MMV006767, Figure 4A ). It is unclear whether the poor activity seen in our screen is the result of use of a different parasite strain in our assay (3D7 versus W2mef), the buffer conditions used or differences in the 5'UTR. The validated translation inhibitor DDD107498, however, showed potent activity leading to a 73.5% inhibition of translation in our assay ( Figure   4A ). This further validates the breadth of activity detectable in our IVT assay, whilst suggesting that the Malaria Box is unlikely to have a potent translation inhibitor in its collection.
Finally, having verified the activity of our IVT platform for screening, we sought to undertake a blind HTP screen of untested compounds as validation for future screening of entire compound libraries. Table 1 ). One exception was a single compound identified as effectively reducing translation by ±99% ( Figure 4B , compound A14). On un-blinding, this compound was revealed to be Puromycin, a drug known to inhibit protein translation, which has been previously shown to have nanomolar activity against P. falciparum 21 .
In conclusion, we have optimized a cell free lysate for HTP IVT that reconstitutes the complete parasite translation machinery. The IVT assay is validated as effective in detecting compounds that inhibit ribosome activity directly (Emetine, Cycloheximide and Puromycin), ribosome co-factors (e.g. the recently identified compound DDD107498, targeting elongation factor elongation factor 2 (eEF2)) and tRNA synthetases (Halofuginone). We also describe the first blind screen for translation inhibitors using a small library of compounds enriched for anti-microbial activity, which although unable to find a new antimalarial hit successfully, found the only known translation inhibitor (Puromycin) in a blinded array of 247 compounds. This validates our HTP IVT platform, with potential to scale to several thousand compounds per week, for its ability to screen novel drug libraries for hits targeting malaria parasite protein translation. In continuous-read format, the IVT platform has the potential of providing immediate insights into the characteristics of each potential hit, where drugs of different mechanism may be revealed through the interrogation of their kinetic traces -a concept we are currently exploring. We believe the HTP IVT platform will provide a powerful addition to the antimalarial drug discovery pipeline.
MATERIALS AND METHODS

Vectors for in vitro mRNA production
Final plasmid sequences are available upon request. Maps are given in Supplementary Figure   S1B . Lysed pellets were centrifuged at 4 °C 2800×g for 10 min and washed with ice-cold PWB. Wash steps were repeated until supernatant lost its red stain. Parasite pellets were either shock frozen and stored at -80ºC for no longer than 1 month or immediately used for lysate production.
Production of Plasmodium falciparum IVT lysate. Washed pellets were re-suspended in 1-1.5 x pellet volumes of PWB supplemented with 1× EGTA-free protease inhibitor cocktail (Roche) and filled into a 45 mL pre-chilled nitrogen cavitation chamber (Parr Instrument Company) and incubated on ice at 1500 psi for 45 min. After release from the chamber the crude lysate was clarified by differential centrifugation, 15 min at 10,000×g followed by 15 min at 30,000xg at 4˚C.
As a measure for activity, the RNA content of the supernatant was checked using nanospectroscopy (Thermo Fisher Scientific). Lysates with a concentration above 1000 ng/µl were stored in aliquots of 100 µl at −80 °C. IVT reactions were carried out in low volume 384-well plates (Coring #3820 or Greiner BioOne #784101). DMSO and drugs were dispensed prior to assay assembly and plates were with sealed and stored at -20˚C for up to 2 weeks. IVT components were dispensed using an ECHO 525 acoustic dispersion system (SynbiCITE, Imperial College London, UK) and incubated on drug for 15 min prior to addition of customized luciferase reaction buffer. Plates were then immediately transferred into a plate reader (Labtech, Tecan M200 Pro) and detection of luminescence in each well was carried out every 10 min over 5 h, while the sample was incubated at 37˚C and shaken before every time-point. and washed by re-suspension in 5 x cell pellet volume PWB. After a subsequent centrifugation for 15 min at 2.500 x g, 4 °C (Eppendorf), cell pellets were either shock frozen and stored at -80ºC for no longer than 6 months or immediately used for lysate production. Production of the IVT lysate, in vitro translation and luciferase assay were performed as described above with the exception that the mRNA for human IVT was transcribed from a pT7CFE vector (Thermo Fisher Scientific) so that the firefly luciferase was flanked by a EMCV IRES at the 5' UTR and a poly adenyl tail. 
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